Compare Dow Jones Industrial Average ETF (DIA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Neurocrine Biosciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $537.88, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DIA | NBIX | |
|---|---|---|
52-Week High | $542.79 | $185.50 |
52-Week Low | $444.64 | $123.10 |
Market Cap | — | $16.76B |
Sector | — | Health |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $539.70, up 0.28% today, with a bullish technical signal from moving averages and key support at $538. Recent dividends include $1.41 paid in July 2026, reflecting income stability. The stock benefits from broad market momentum, as highlighted by ETF inflows into U.S. equities (ETF Trends, August 7, 2026).
Outlook remains positive due to technical strength and defensive positioning in blue-chip ETFs, but overbought RSI levels near 86 suggest short-term caution. Risks include market volatility from Fed policy and geopolitical tensions, though institutional support provides a cushion for long-term holders.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
